fda warning bpc-157 peptide 2024 2025 Approval Status: Is It Approved for Human Use? Most people hear “not FDA
Description
Diagnoses included osteoarthritis (55.5 percent), chronic low back pain (51.5 percent), and neuropathic pain (24.8 percent, primarily in the feet)
If two formulations are otherwise identical except for B12 form, the methylcobalamin version will be more expensive
Additional considerations include the comfort of the subject
Retrieved February 16, 2022
